Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-03-2008 | EDITORIAL COMMENTARY

Can cardiac iodine-123 metaiodobenzylguanidine imaging contribute to risk stratification in heart failure patients?

Authors: Jeroen J. Bax, Mark Boogers, Maureen M. Henneman

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2008

Excerpt

Chronic heart failure represents a major challenge in clinical cardiology in terms of the number of patients involved. Over the past years, the number of heart failure patients has increased exponentially, with recent estimations indicating that five million patients in the United States have chronic heart failure, with 550,000 new patients diagnosed annually, resulting in one million hospitalizations [1]. The diagnostic and therapeutic costs involved with heart failure are estimated to be more than $ 29 billion per year [1]. The major part of costs appears related to hospitalizations for decompensated heart failure. …

American Heart Association. Heart disease and stroke statistics, 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–151.CrossRef

Gheorghiade M, Bonow RO. Chronic heart failure in the United States. A manifestation of coronary artery disease. Circulation. 1998;97:282–9.PubMed

Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–402.PubMedCrossRef

Hartmann F, Ziegler S, Nekolla S, Hadamitzky M, Seyfarth M, Richardt G, et al. Regional patterns of myocardial sympathetic denervation in dilated cardiomyopathy: an analysis using carbon-11 hydroxyephedrine and positron emission tomography. Heart. 1999;81:262–70.PubMed

Bengel FM, Schwaiger M. Assessment of cardiac sympathetic neuronal function using PET imaging. J Nucl Cardiol. 2004;11:603–16.PubMedCrossRef

Bengel FM, Permanetter B, Ungerer M, Nekolla S, Schwaiger M. Relationship between altered sympathetic innervation, oxidative metabolism and contractile function in the cardiomyopathic human heart; a non-invasive study using positron emission tomography. Eur Heart J. 2001;22:1594–600.PubMedCrossRef

Pietila M, Malminiemi K, Ukkonen H, Saraste M, Någren K, Lehikoinen P, et al. Reduced myocardial carbon-11 hydroxyephedrine retention is associated with poor prognosis in chronic heart failure. Eur J Nucl Med. 2001;28:373–6.PubMedCrossRef

Flotats A, Carrio I. Cardiac neurotransmission SPECT imaging. J Nucl Cardiol. 2004;11:587–602.PubMedCrossRef

Carrio I. Cardiac neurotransmission imaging. J Nucl Med. 2001;42:1062–76.PubMed

10.

Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, et al. Myocardial imaging with a radio-iodinated norepinephrine storage analog. J Nucl Med. 1981;22:22–31.PubMed

11.

Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471–7.PubMed

12.

Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Randé JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med. 1999;40:917–23.PubMed

13.

Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol. 1999;33:759–66.PubMedCrossRef

14.

Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol. 1998;5:579–90.PubMedCrossRef

15.

Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac events. J Nucl Med. 2001;42:1757–67.PubMed

16.

Ogita H, Shimonagata T, Fukunami M, Kumagai K, Yamada T, Asano Y, et al. Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart. 2001;86:656–60.PubMedCrossRef

17.

Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol. 2003;41:231–8.PubMedCrossRef

18.

Anastasiou-Nana MI, Terrovitis JV, Athanasoulis T, Karaloizos L, Geramoutsos A, Pappa L, et al. Prognostic value of iodine-123-metaiodobenzylguanidine myocardial uptake and heart rate variability in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2005;96:427–31.PubMedCrossRef

19.

Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multi-center study. Eur J Nucl Med Mol Imaging. 2007. DOI 10.1007/s00259-007-0639-3.

Title: Can cardiac iodine-123 metaiodobenzylguanidine imaging contribute to risk stratification in heart failure patients?
Authors: Jeroen J. Bax
Mark Boogers
Maureen M. Henneman
Publication date: 01-03-2008
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0722-4

At a glance: The STEP trials

Springer Medicine

Can cardiac iodine-123 metaiodobenzylguanidine imaging contribute to risk stratification in heart failure patients?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2008

Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer

Variations in 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation

Society communication

Evolving concept of imaging bone marrow metastasis in the twenty-first century: critical role of FDG-PET

Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer

Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer